Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael T. Beste
Michael T. Beste
Novartis
Internal medicine
Medicine
Canakinumab
Anesthesia
Omalizumab
4
Papers
33
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial.
2021
Huilei Xu
Claudia Hon
Sergio Kaiser
Pablo Serrano-Fernandez
Nicole Hartmann
Denise Yates
Margaret L Healey
Arkady I Gusev
Jason M. Laramie
Scott Kennedy
Philippe Marc
Paul M. Ridker
Ma’en Obeidat
Michael T. Beste
Eric C Svensson
Aviv Madar
Show All
Source
Cite
Save
Citations (0)
Inhibition of IL-1β by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial.
2020
Cancer Research
Connie C. Wong
Jason Baum
Angela Silvestro
Michael T. Beste
Bharani Bharani-Dharan
Siyan Xu
Ying A Wang
Xiaoshan Wang
Margaret F. Prescott
Lynne Krajkovich
Margaret Dugan
Paul M. Ridker
Anne Marie Martin
Eric C Svensson
Show All
Source
Cite
Save
Citations (12)
Endometrioma, the Follicular Fluid Inflammatory Network, and its Association with Oocyte and Embryo Characteristics
2019
Reproductive Biomedicine Online
Jennifer Yland
Luiz Carvalho
Michael T. Beste
A.P. Bailey
Cassandra Thomas
Mauricio Simões Abrão
Catherine Racowsky
Linda G. Griffith
Stacey A. Missmer
Show All
Source
Cite
Save
Citations (6)
Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double‐blind, placebo‐controlled study
2019
Allergy
Martin Metz
Rebecca Torene
Sergio Kaiser
Michael T. Beste
Petra Staubach
Andrea Bauer
Randolf Brehler
Janine Gericke
Martin Letzkus
Nicole Hartmann
Veit J. Erpenbeck
Marcus Maurer
Show All
Source
Cite
Save
Citations (15)
1